spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Fabry disease 

 HSMN NewsFeed - 18 Mar 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 24 Feb 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Apr 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2021
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 30 Dec 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 May 2020
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2018
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 27 Dec 2017
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Mar 2017
BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2015
Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2015
Amicus Therapeutics Strengthens Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2015
Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold(TM) (Migalastat) in European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2013
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Dec 2012
Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2011
NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2011
Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2011
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
Biopharmaceuticals
 HSMN NewsFeed - 30 Aug 2010
Genzyme Confirms Receipt of Unsolicited Proposal
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Feb 2010
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 5 Feb 2010
Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2009
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2009
William Aliski Named FoldRx Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2009
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2007
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Oct 2007
Genzyme Receives Approval to Market Elaprase(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Aug 2007
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 22 May 2007
Shire Human Genetic Therapies AB Signs Exclusive Marketing and Distribution Deal With Samaritan to Launch REPLAGAL for Fabry Disease in Greece and Cyprus
Biopharmaceuticals Distribution
 HSMN NewsFeed - 16 May 2007
Genzyme Announces Positive Initial Observations in Trial Evaluating Novel Oral Treatment for Gaucher Disease
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2007
Amicus Therapeutics Announces Return of John F. Crowley as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2007
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
Amicus Therapeutics Appoints Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Sep 2006
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 5 Jul 2006
Amicus Therapeutics Adds Glenn P. Sblendorio to Board of Directors
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 33

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 33 additional stories matching:
Fabry disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.